Egis in the World
Egis’ products reach 100 countries.
Our portfolio contains 653 products. Our highlighted therapeutical areas are the cardiovascular system, the central nervous system and the respiratory system.
Learn moreEgis activities extend to every field of the pharmaceutical value chain
Click here to learn moreInnovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 business year.
Click here to learn moreCsaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.
The pharmaceutical industry plays a key role in the Hungarian economy’s change of dimension.